The test mitigates the potential interference in visualisation of M-proteins in immunofixation electrophoresis caused by DARZALEX.
DARZALEX is a human monoclonal antibody targeting CD38 that provides superior clinical benefit to monotherapy in heavily pre-treated multiple myeloma (MM) patients and when combined with standard of care regimens for the treatment of MM.
sebia.com
